Evidence map›Paper›PMID 36747713›Full record

ArticlebioRxiv : the preprint server for biology2023

Combined KRAS

Venu Thatikonda, Hengyu Lu, Sabine Jurado, Kaja Kostyrko, Christopher A Bristow, Karin Bosch, Ningping Feng, Sisi Gao, Daniel Gerlach, Michael Gmachl and 18 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

28 authors at 2 institutions in 2 countries.

Venu ThatikondaBoehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
Hengyu LuTranslational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sabine JuradoBoehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
Kaja KostyrkoBoehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
Christopher A BristowTranslational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Karin BoschBoehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
Ningping FengTranslational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sisi GaoTranslational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Daniel GerlachBoehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
Michael GmachlBoehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
Simone LiebBoehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
Astrid JeschkoBoehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
Annette A MachadoTranslational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ethan D MarszalekTranslational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Mikhila MahendraTranslational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Philipp A JaegerBoehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
Alexey SorokinDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sandra StraussBoehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
Francesca TrapaniBoehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
Scott KopetzDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Christopher P VellanoTranslational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Mark PetronczkiBoehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
Norbert KrautBoehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
Timothy P HeffernanTranslational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Joseph R MarszalekTranslational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Mark PearsonBoehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
Irene WaizeneggerBoehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
Marco H HofmannBoehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
Boehringer Ingelheim (Austria) · ATThe University of Texas MD Anderson Cancer Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

Efforts to improve the anti-tumor response to KRAS

Identifiers

PMID36747713
PMCPMC9900819
OpenAlexW4317788291

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.